Opinion|Videos|July 31, 2024
The Heterogeneity of Prostate Cancer
Experts on prostate cancer discuss the heterogeneity of the disease and the rationale for using medications with different mechanisms of action, including androgen deprivation therapy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
2
Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer
3
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
4
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
5